The findings highlight the importance of having an EP versed in lead management on the heart valve team, one expert says.

The procedures are not mutually exclusive, however, and should be considered on a patient-by-patient basis, a researcher says ...

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

This month: pharmacy’s growing CICU role, arrhythmias’ impact on pregnancy, Life’s Essential 8 in practice, and more.

PanEcho isn’t yet ready to be a standalone tool, researchers say, but shows promise at improving workflows and patient care.

In an early look at SCOT-HEART 2, CCTA led more primary-prevention patients to make changes to reduce their risk of CVD.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

In DETECT AS, the passive notifications improved rates of AVR and boosted survival, with bigger gains in women.

The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.